FUSION FPX-01-01
10 Dec 2020
Trial Summary
This is a first-in-human Phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547.
Acronym:
FPX-01-01
ACTRN/NCT /ethics:
NCT03746431
Scientific title:
A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours
Sponsor / Cooperative group:
Fusion Pharmaceuticals
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Advanced Solid Tumors |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2019-01-17 |
| Anticipated End Date | 2021-01-31 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |